期刊文献+

薄层液基细胞学和阴道镜筛查宫颈病变的临床价值

下载PDF
导出
摘要 目的探讨薄层液基细胞学和阴道镜筛查宫颈病变的临床价值。方法选择2010-2012年在丹阳市第二人民医院妇科就诊的5937例患者,宫颈病变筛查分别采用薄层液基细胞学(TCT)检测和阴道镜检查,对TCT检测为不明意义的不典型鳞状上皮(ASCUS)、鳞状上皮内病变(SIL)、鳞状细胞癌(SCC),阴道镜检测为异常图像的病例行宫颈活组织病理学检查。结果 268例TCT为ASCUS以上者,其中病理诊断慢性宫颈炎219例(符合率88.1%),宫颈上皮内瘤变Ⅰ级34例(符合率67.6%),宫颈上皮内瘤变Ⅱ-Ⅲ级13例(符合率76.9%),宫颈癌2例(符合率100%)。1111例阴道镜异常图像,其中病理诊断慢性宫颈炎993例(符合率96.8%),宫颈上皮内瘤变115例(符合率90.4%),宫颈癌3例(符合率66.7%)。结论 TCT检测与宫颈活组织病理诊断结果总符合率83.2%,阴道镜检查与宫颈活组织病理诊断结果总符合率84.6%。TCT检测和阴道镜检查对筛查女性宫颈疾病准确、可靠,有重要价值。
作者 孔林花
出处 《中国妇幼卫生杂志》 2013年第2期62-63,共2页 Chinese Journal of Women and Children Health
  • 相关文献

参考文献4

二级参考文献40

  • 1岑坚敏,钱德英,曾仁海,洪淡华.影视阴道镜下RCI评分对宫颈上皮内瘤变的诊断价值[J].广东医学,2004,25(11):1290-1292. 被引量:9
  • 2Jack C, Christine C, Karl-Ulrich P, et al. Overview of the european and north american studies on HPV testing in primary cervical cancer screening[ J]. International Journal of Cancer, 2006,119 ( 5 ) : 1095- 1101.
  • 3QIAO You-lin,ZHANG Lin-qi.The discovery of HPV causing cervical cancer and HIV-Commentary on the nobel prize in physiology or medcine for 2008:2009 Science Development Report[R].Beijing:Chinese Academy of Science Press,2009:112-119.
  • 4Sankaranarayanan R,Esmy P O,Rajkumar R,et al.Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu,India:A cluste-randomised trial[J].Lancet,2007,370(9585):398-406.
  • 5Oikonomou P,Mademtzis I,Messinis I,et al.Quantitative determination of human telomerase reverse transcriptase messenger RNA expression in premalignant cervical lesions and correlation with human papillomavirus load[J].Hum Pathol,2006,37(2):135-142.
  • 6Andersson,Wallin K L,Hellstrom A C,et al.Frequent gain of the human telomerase gene TERC at 3q26 in cervical adenocarcinomas[J].British Journal of Cancer,2006,95(3):331-338.
  • 7Nancy P,Caraway A K,Marilyn D,et al.Gain of the 3q26 region in cervicovaginal liquid-based pap preparations isassociated with squamous intraep ithelial lesions and squamous cell carcinoma[J].Gynecologic Oncology,2008,(1):37-42.
  • 8Siddiqui M A,Perry C M.Human papillomavirus quadrivalent(types6,11,16,18)recombinant vaccine(Gardasil)[J].Drugs,2006,66(9):1263-1271.
  • 9Stan L,Darron R,Archana B,et al.Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus(Types 6,11,16,and 18) L1 virus-like particle vaccine[J].The Pediatric Infectious Disease Journal,2010,29(2):1-7.
  • 10Suba E J,Raab S S,Frable W J,et al.Cost-effectiveness of cervicalcancer screening in developing countries[J].N Engl J Med,2006,354(14):1535-1536.

共引文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部